NPS closes public offering, as it expects net proceeds of $107M
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals, which focuses on therapies for rare GI and endocrine disorders, has completed its previously announced public offering, a follow on underwritten by CitiGroup Capital Markets and Leerink Swann. The price was $9 per share, and the final offering covered 12,650,000 shares, which included 1,650,000 shares sold as per the full exercise of an option granted to the underwriters.